5969-49-3Relevant academic research and scientific papers
Discovery of Pyrazolocarboxamides as Potent and Selective Receptor Interacting Protein 2 (RIP2) Kinase Inhibitors
Haffner, Curt D.,Charnley, Adam K.,Aquino, Christopher J.,Casillas, Linda,Convery, Máire A.,Cox, Julie A.,Elban, Mark A.,Goodwin, Nicole C.,Gough, Peter J.,Haile, Pamela A.,Hughes, Terry V.,Knapp-Reed, Beth,Kreatsoulas, Constantine,Lakdawala, Ami S.,Li, Huijie,Lian, Yiqian,Lipshutz, David,Mehlmann, John F.,Ouellette, Michael,Romano, Joseph,Shewchuk, Lisa,Shu, Arthur,Votta, Bartholomew J.,Zhou, Huiqiang,Bertin, John,Marquis, Robert W.
, p. 1518 - 1523 (2019)
Herein we report the discovery of pyrazolocarboxamides as novel, potent, and kinase selective inhibitors of receptor interacting protein 2 kinase (RIP2). Fragment based screening and design principles led to the identification of the inhibitor series, and X-ray crystallography was used to inform key structural changes. Through key substitutions about the N1 and C5 N positions on the pyrazole ring significant kinase selectivity and potency were achieved. Bridged bicyclic pyrazolocarboxamide 11 represents a selective and potent inhibitor of RIP2 and will allow for a more detailed investigation of RIP2 inhibition as a therapeutic target for autoinflammatory disorders.
